Investor Presentaiton

Top-tier talent Differentiated process Scalable platform Maintaining a disciplined investment process Increasing inbounds lead to greater initial reviews Streamlined and efficient review process High quality bar for in-depth reviews Expanding number of synthetic royalty reviews Increasing market awareness of royalty funding Outbound calls still drive majority of transactions Selective on development-stage therapies we pursue Balance between pre-existing and synthetic royalties Approved Pre-approval Pre-existing Synthetics Initial reviews (2021) ~20% ~25% ~80% ~75% Outbound Inbound ~20% ~80% Approved Pre-approval Pre-existing Synthetics Outbound Inbound In-depth reviews (2021) ~30% ~45% ~55% ~40% ~60% ~70% ROYALTY PHARMA 62 62

View entire presentation